Bio Rad Laboratories Inc expected to post earnings of $2.01 a share - Earnings Preview

Bio-Rad Laboratories

30/07/2024 22:00

* Bio Rad Laboratories Inc  BIO.N   BIO  is expected to show
a
fall in quarterly revenue when it reports  results on August 1
for the period ending June 30 2024
    * The Hercules California-based  company is expected to
report a
5.2% decrease in revenue to $645.789 million from $681.11
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Bio Rad Laboratories Inc
is
for earnings of $2.01 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bio Rad
Laboratories Inc is $315.00​, below​ its last closing price
of $340.23. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   2.10        2.15       2.29      Beat    6.7
 Jan. 1 0001   2.81        2.82       3.10      Beat    10
 Sep. 30 2023  2.81        2.78       2.33      Missed  -16.3​
 Jan. 1 0001   2.68        2.68       3.00      Beat    12
 ​​Jan.        3.59        3.54       3.34      Missed  -5.7
 1 0001                                                 
 Dec. 31 2022  3.43        3.45       3.31      Missed  -4​
 Jan. 1 0001   2.83        2.78       2.60      Missed  -6.5
 Jan. 1 0001   2.90        2.80       3.38      Beat    20.8
 This summary was machine generated July 30 at 21:00 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)